Search Clinical Trials in the European Union
Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
681-700 of 1,782 trials
Advanced Non-Small Cell Lung CancerEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology
Nephroblastoma6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesNephrologyOncologyPediatrics
Implantation of Cardiac Devices1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology
Pancreatic Ductal Cancer6-12 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyOncology
Hematological Malignancies>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyInfectious Diseases
Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics
Active Ulcerative Colitis or Crohn's Disease>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterology
Acute Myeloid Leukemia (AML)Myelodysplastic Neoplasia (MDS)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology
Septic Shock1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrologyPulmonology
Stage III/IV Non-Small-Cell Lung Cancer with ROS1 Rearrangement>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteOncologyPulmonology
Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine
Temporomandibular Joint Arthritis3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesOrthopedics and Traumatology
Pulmonary Arterial Hypertension>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiology
Systemic Lupus Erythematosus>2 yearsMonitoring phase (IV)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteRheumatology
Chronic Kidney Disease3-6 monthsMonitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementInternal MedicineNephrology
Extrahepatic Cholangiocarcinoma>2 yearsEfficacy phase (II)>20 visitsNo PlaceboStandard MedicinesGastroenterologyOncology
Avian Influenza and Seasonal Influenza1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology
Hand Osteoarthritis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineRheumatology